## Comparison of <sup>18</sup>F-PSMA-1007 with <sup>18</sup>F-Choline PET/CT in Prostate Cancer Recurrence, using Quantitative Biomarkers

- 1. Laboratory of Medical Physics and Digital Innovation, Aristotle University of Thessaloniki, Thessaloniki, Greece
- 2. Nuclear Medicine PET/CT Department 'Theageneio' Cancer Center, Thessaloniki, Greece 3. Department of Physics, Aristotle University of Thessaloniki, Thessaloniki, Greece

### Background

The aim of this study is to compare morphological and quantitative features of <sup>18</sup>F-PSMA-1007 and <sup>18</sup>F-Choline PET/CT in prostate cancer (PCa) patients with biochemical recurrence (BCR) enrolled in the BIO-CT-001 trial.

# **Materials & Methods**

- **106 patients** who had undergone primary treatment for PCa.
- One <sup>18</sup>F-PSMA-1007 and one <sup>18</sup>F-Choline PET/CT examination within 10 days.
- LifeX software to extract: **SUVmax**, **SUVmean**, total volume of the lesion (PSMA-TV/FCH-TV) the total lesion uptake (TL-PSMA/TL-FCH) for all identified metastatic lesions.

### Results

- **286** lesions were identified of which 49.0% were lymph node metastases (LN), <u>41.2% were bone</u> metastases (BN) and <u>9.8%</u> involved locoregional (PR) recurrences of PCa.
- The median SUVmax value was significantly higher for PSMA ulletcompared to Choline for all lesions.
- Statistically significant differences in median SUVmean, PSMA/FCH-TV and TL-PSMA/FCH between the two radiotracers.

# Conclusion

Our analysis demonstrated the **improved performance of <sup>18</sup>F-PSMA-1007 compared to** <sup>18</sup>**F-Choline** for calculating quantitative features in all metastatic lesions in PCa patients with BCR.

Sotiria Andreou<sup>1</sup>, Emmanouil Panagiotidis<sup>2</sup>, Kira Aggeioplasti<sup>3</sup>, Anna Makridou<sup>4</sup>, Ioannis Datseris<sup>5</sup>, Vasiliki Chatzipavlidou<sup>2</sup>, Emmanouil Papanastasiou<sup>1</sup> 4. Department of Medical Physics, Cancer Hospital of Thessaloniki Theageneio, Thessaloniki, Greece 5. Department of Nuclear Medicine, Evangelismos General Hospital, Athens, Greece







ax 1)	PSMA/FCH- TV (cm <sup>3</sup> )	TL-PSMA/FCH (cm <sup>3</sup> *gr/ml)
3.31)	7.31 (0.34-435.27)	1.97 (0.17-48.07)
34.26)	4.37 (0.07-560.3)	1.53 (0.17-94.37)
)1	p<0.001	p<0.001